tag influenza 
Pharmaceutical Technology
MAY 15, 2023
Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing.
The Pharma Data
JANUARY 31, 2021
Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. About Trimer-Tag© Technology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JANUARY 31, 2021
Utilizing Clover’s proprietary Trimer-Tag© technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. About Trimer-Tag© Technology.
Rethinking Clinical Trials
SEPTEMBER 22, 2022
The DANFLU-1 trial evaluated the feasibility of integrating an individually randomized trial into routine seasonal influenza vaccination practice using administrative health registries for data collection. 34,000 study invitations were sent out and 12,551 participants consented and were randomized in the study. Learn more.
The Pharma Data
DECEMBER 3, 2020
Utilizing Clover’s proprietary Trimer-Tag © technology, S-Trimer is a trimeric SARS-CoV-2 spike (S)-protein subunit vaccine candidate. Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. About Trimer-Tag © Technology.
Expert insights. Personalized for you.
130 
Let's personalize your content